Browsing by Autor "Elizabeth Wu"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item type: Item , Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma(Taylor & Francis, 2026) Javier Pinilla-Ibarz; Mei Xue; Elizabeth Wu; Kaitlyn Esselman; Wesley Furnback; Swetha Challagulla; Keri YangZanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs acalabrutinib and ibrutinib in 1L and 2L.